The Center for Personalized Diagnostics (CPD) opened its doors for business on February 14, 2013. Since then, the CPD has issued more than 8,000 reports through its custom hematologic malignancy panel with 68 genes, focused primarily on AML, MDS and CLL, and a more comprehensive solid tumor panel, containing 153 genes known to be mutated in a wide range of tumor types. The CPD diagnostics reports represent a wide range of cancers: 24% lung cancer, 21% gastrointestinal cancers, 15% acute myeloid leukemia, 13% brain cancers, 8% melanoma, 19% other cancers (breast, thyroid, other). To maintain its position at the leading edge of implementing genomic technologies in a clinical environment, the CPD has developed the use of residual FNA rinse and body fluid specimens for next-generation sequencing and is developing single cell genomic analyses, analysis of cell-free tumor DNA and both exome and whole genome sequencing of a variety of tumor types.